Related Experiment Videos
Interaction between free fatty acids and glucose metabolism
1Division of Endocrinology/Diabetes/Metabolism and the General Clinical Research Center, Temple University School of Medicine, Philadelphia, Pennsylvania 19140, USA.. bodengh@tuhs.temple.edu
Current Opinion in Clinical Nutrition and Metabolic Care
|August 13, 2002
Summary
Elevated free fatty acids (FFAs) contribute significantly to insulin resistance and type 2 diabetes. Lowering FFAs or blocking their pathways may offer new therapeutic strategies for managing this metabolic disorder.
Area of Science:
- Metabolic Research
- Endocrinology
- Molecular Biology
Background:
- Obesity and type 2 diabetes mellitus (T2DM) prevalence is rising globally.
- Free fatty acids (FFAs) are increasingly recognized as a key link between obesity and insulin resistance.
- Understanding FFA and glucose metabolism interactions is crucial for metabolic disease research.
Purpose of the Study:
- To review the complex interactions between free fatty acids (FFAs) and glucose metabolism.
- To elucidate the role of FFAs in the development of insulin resistance and type 2 diabetes mellitus.
- To explore potential therapeutic targets related to FFA metabolism in T2DM.
Main Methods:
- Review of existing literature on FFA metabolism and insulin resistance.
- Analysis of molecular mechanisms linking FFAs to impaired insulin signaling in muscle and liver.
- Examination of FFA effects on pancreatic beta-cell function.
Main Results:
- Elevated plasma FFAs induce peripheral and hepatic insulin resistance.
- In skeletal muscle, FFAs promote intramyocellular lipid accumulation and activate protein kinase C, potentially disrupting insulin signaling.
- In the liver, FFAs impair insulin's ability to suppress glucose production.
- FFAs enhance glucose-stimulated insulin secretion from beta cells, potentially protecting against T2DM in some individuals.
Conclusions:
- Plasma FFAs account for a substantial portion (up to 50%) of insulin resistance in obese patients with T2DM.
- Targeting FFAs or their downstream signaling pathways presents a promising therapeutic avenue for T2DM treatment.